Liquidia Corp.: Prime Candidate For A Takeout By Large Pharma (LQDA)
Summary
Liquidia sees strong YUTREPIA sales growth despite an ongoing patent battle with United Therapeutics. Read the full analysis for more details.
Description
Liquidia sees strong YUTREPIA sales growth despite an ongoing patent battle with United Therapeutics. Read the full analysis for more details.
Original reporting
AFBytes is a read-only aggregator. Use the original source for full context and complete reporting.
Open original source